Stereotaxis to highlight new clinical results at HRS 2016

254

Stereotaxis will share results of recently published clinical studies, new technology enhancements, user experiences, and simulations of its computer-controlled mapping and lesion formation capabilities at 37th Annual Heart Rhythm Society (HRS) Scientific Sessions.

“We are excited to bring together expert users of our remote magnetic navigation platform and physicians searching for treatment options that provide improved outcomes for complex cardiac arrhythmias with a lower risk of adverse events and reduced fluoro exposure to patients and physicians,” says William C Mills, Stereotaxis chief executive officer.

Stereotaxis will host a lunch during th econference, featuring the latest insights and clinical research by experienced users. Chaired by Mauricio Arruda (University Hospitals Case Medical Center, Cleveland, USA), who has completed more than 1,200 procedures using the Niobe remote magnetic navigation system, the session will clinical results of the system in the treatment of ischaemic and non-ischaemic ventricular tachycardia (VT) patients, as well as a discussion of the company’s multicentre, randomised, superiority study of VT ablation outcomes. Guest speakers include Luigi Di Biase (Albert Einstein College of Medicine at Montefiore Hospital, Bronx, USA), Hiroshi Nakagawa (Oklahoma University Medical Center, Oklahoma City, USA), and Tamas Szili-Torok (Erasmus Medical Center, Rotterdam, Netherlands).

In its exhibit space, Stereotaxis will highlight its Niobe system, focusing on the next-generation user interface, which includes new features such as improved catheter tip-to-tissue contact confirmation based on bipolar impedance information. During the HRS Rhythm Theatre,Nakagawa will also share the development progress for the lesion assessment and prediction tool called Magnetic Ablation Index. Each of these software features are designed to provide valuable information to physicians while they are ablating tissue, and also furthers the ongoing efforts to fully automate the execution of physician-defined ablation strategies.

Finally, the company will unveil its newly developed, software-based simulation platform for physician training, alongside a modelled beating heart phantom that demonstrates the mechanics of its technologies in effective lesion creation within the most difficult to reach and navigate regions of the heart.

(Visited 37 times, 1 visits today)